Global Preclinical Oncology Models Market is valued at USD 1335.7 Million in 2024 and is predicted to reach USD 3733.0 Million by 2034, at a 10.9% CAGR during the forecast period 2025-2034.
The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncology industry with success of CAR-T Therapy boosted the R&D activities in the oncology industry which boost the demand for preclinical oncology models such as humanized models and syngeneic tumor models. The need for predictive approaches and robust preclinical models to minimize translational failures in immuno-oncology is very high. The factors such as early identification of predictive biomarkers, leveraging phenotypic features of models, and the need of rational design of combination therapies drive the growth of the oncology preclinical models market.
The global oncology preclinical models market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Syngeneic Models, Cell Lines Models, Orthotopic Tumor Models, and Others based on application type, the market is segmented into Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1335.7 Million |
|
Revenue Forecast In 2034 |
USD 3733.0 Million |
|
Growth Rate CAGR |
CAGR of 10.9% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., and The Jackson Laboratory |
|
Customization Scope |
Free customization report with the procurement of the report, modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Preclinical Oncology Models Market Snapshot
Chapter 4. Global Preclinical Oncology Models Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Analysis of Key Vendors in Cancer Clinical Trial/Pipeline
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape
4.8. Major Investment, Partnerships and Collaborations in Cancer Research
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Patient-Derived Xenograft Models (PDX)
5.2.2. Cell Line Derived Xenograft Models
5.2.3. Syngeneic Models
5.2.4. Genetically engineered mouse models (GEMMs)
5.2.5. Orthotopic Models
5.2.6. Custom Xenograft and Syngeneic Model
5.2.7. Others
Chapter 6. Market Segmentation 2: Application Estimates & Trend Analysis
6.1. Application Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Neuroblastoma
6.2.2. Prostate Cancer
6.2.3. Pancreatic Cancer
6.2.4. Breast Cancer
6.2.5. Colorectal Cancer
6.2.6. Bladder Cancer
6.2.7. Fibrosarcoma
6.2.8. Kidney Cancer
6.2.9. Liver Cancer
6.2.10. Lung Cancer
6.2.11. Lymphoma
6.2.12. Skin Cancer
6.2.13. Others
Chapter 7. Preclinical Oncology Models Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by product, 2021-2034
7.1.2. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by application, 2021-2034
7.1.3. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Preclinical Oncology Models Market revenue (US$ Million) by product, 2021-2034
7.2.2. Europe Preclinical Oncology Models Market revenue (US$ Million) by application, 2021-2034
7.2.3. Europe Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. France
7.2.3.3. Italy
7.2.3.4. Spain
7.2.3.5. UK
7.2.3.6. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by product, 2021-2034
7.3.2. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by application, 2021-2034
7.3.3. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Rest of World
7.4.1. Rest of World Preclinical Oncology Models Market revenue (US$ Million) by product, 2021-2034
7.4.2. Rest of World Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
7.4.2.1. Latin America
7.4.2.2. Middle East & Africa
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Aragen Bioscience
8.2.2. vivoPharm Pty. Ltd.
8.2.3. Bisoduro
8.2.4. Crown Bioscience Inc.
8.2.5. Charles River
8.2.6. Champion Oncology, Inc.
8.2.7. Envigo (Inotive Inc.)
8.2.8. GenOway S.A.
8.2.9. Hera Biolabs, Inc.
8.2.10. MI Bioresearch (Labcorp Inc.)
8.2.11. Pharmatest Services
8.2.12. Taconic Biosciences, Inc
8.2.13. The Jackson Laboratory
8.2.14. Reaction Biology(ProQinase GmbH)
8.2.15. Creative Animodel
8.2.16. Biocytogen
8.2.17. Oncodesign Services
8.2.18. WuXi AppTec
8.2.19. Washington Biotechnology Inc.
8.2.20. XenTech.eu
8.2.21. Other Prominent Player List of Other Prominent Players
Global Preclinical Oncology Models Market by Product
Global Preclinical Oncology Models Market Based on Application
Global Preclinical Oncology Models Market Based on Region
Europe Preclinical Oncology Models Market Revenue Outlook
North America Preclinical Oncology Models Market Revenue Outlook
Asia Pacific Preclinical Oncology Models Market Revenue Outlook
Latin America Preclinical Oncology Models Market Revenue Outlook
Middle East & Africa Preclinical Oncology Models Market Revenue Outlook
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
